

1 SENATE RESOLUTION

2 WHEREAS, The Illinois Department of Public Aid (IDPA) has
3 entered into a contract to create a Preferred Drug List in
4 the Medicaid program to entice pharmaceutical manufacturers
5 into providing supplemental rebates to the program; and

6 WHEREAS, The establishment of a Medicaid Preferred Drug
7 List will necessitate a vast expansion in prior authorization
8 of prescription drugs, which inherently limits access of
9 Medicaid patients to certain prescription medications; and

10 WHEREAS, The creation of an Illinois Medicaid Preferred
11 Drug List could radically alter the clinical integrity of
12 formularies and the treatment regimens of Illinois' Medicaid
13 patients and lead to unintended and costly consequences such
14 as inferior healthcare, increased hospitalizations and
15 emergency care, increased admissions into long-term care, and
16 unnecessary patient suffering and potentially death; and

17 WHEREAS, It could be especially risky to interfere with
18 the treatment regimens of particularly vulnerable
19 populations, including, but not limited to, patients with
20 HIV/AIDS, cancer, or mental illness, children, nursing home
21 residents, and persons with other complex and serious
22 diseases; and

23 WHEREAS, IDPA has moved forward on the creation of a
24 Preferred Drug List without notice to or advice from the
25 Illinois General Assembly and without input from the patient
26 advocate community; therefore, be it

27 RESOLVED, BY THE SENATE OF THE NINETY-SECOND GENERAL
28 ASSEMBLY OF THE STATE OF ILLINOIS, that the Senate Public Aid
29 Preferred Drug List Oversight Committee is established for
30 the purpose of overseeing the implementation of IDPA's
31 Medicaid Preferred Drug List; and be it further

1 RESOLVED, That the Senate Public Aid Preferred Drug List
2 Advisory Committee shall consist of 5 senators, 3 of whom
3 shall be appointed from the majority party by the President
4 of the Senate and 2 of whom shall be appointed from the
5 minority party by the Senate Minority Leader; and be it
6 further

7 RESOLVED, That the Senate Public Aid Preferred Drug List
8 Oversight Committee may do the following:

9 (1) Hold public hearings to receive and consider
10 input from key stakeholders such as physicians, the
11 patient advocacy community, and other interested parties.

12 (2) Solicit data from IDPA and request monthly
13 reports from IDPA on the implementation, health outcomes,
14 and net cost implications of the Medicaid Preferred Drug
15 List, including the cost of any consulting or contractor
16 fees to implement the Preferred Drug List, the cost to
17 conduct prior authorization, and costs to other
18 healthcare services paid for by IDPA, such as emergency
19 care, hospitalization, and long-term care.

20 (3) Make recommendations to IDPA regarding the
21 clinical integrity of drug formularies, patient care, and
22 particular therapeutic classes of drugs that should be
23 exempted from the Preferred Drug List; and be it further

24 RESOLVED, That the Senate Public Aid Preferred Drug List
25 Advisory Committee shall complete its work by December 31,
26 2002.